Issue 8/2014
Content (8 Articles)
Commentary
Transparency in Reimbursement Decisions: In Whose Best Interest?
Tania Stafinski, Devidas Menon
Current Opinion
Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-Effectiveness Analysis in the USA?
James D. Chambers
Practical Application
Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider
Matt D. Stevenson, Peter L. Selby
Systematic Review
Economic Evaluations of Gastroesophageal Reflux Disease Medical Management
Andrew J. Gawron, Dustin D. French, John E. Pandolfino, Colin W. Howden
Systematic Review
A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis
Ayse Kuspinar, Nancy E. Mayo
Open Access
Original Research Article
Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
Alex Diamantopoulos, A. Finckh, T. Huizinga, D. K. Sungher, L. Sawyer, D. Neto, F. Dejonckheere
Original Research Article
The Better than Dead Method: Feasibility and Interpretation of a Valuation Study
R. A. van Hoorn, A. R. T. Donders, M. Oppe, P. F. M. Stalmeier
Original Research Article
A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding
Rosarin Sruamsiri, Piyameth Dilokthornsakul, Chayanin Pratoomsoot, Nathorn Chaiyakunapruk